1 / 2
High-Quality Semaglutide CAS 910463-68-2 - China Suppliers & Factory for Effective Weight Management Solutions Manufacturer, Manufacturers
Product Description
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a class of drugs that have been clinically proven to be effective in helping individuals manage their weight. By mimicking the effects of the natural hormone GLP-1, semaglutide plays a vital role in regulating appetite and blood sugar levels. This innovative approach not only aids in weight loss, but also improves metabolic health, making it a comprehensive solution for those seeking to change their lifestyle.
Mechanism & Efficacy
Semaglutide is a GLP-1 receptor agonist that regulates blood glucose by stimulating insulin secretion and inhibiting glucagon release. It is commonly used in clinical research for type 2 diabetes management, weight management, and obesity-related studies.
Dosage & Clinical Use
Semaglutide (marketed as Wegovy®/Ozempic®) is administered by once‑weekly subcutaneous injection. Common dosing protocols for obesity and weight management range from 0.25 mg up to 2.4 mg weekly, with gradual titration based on tolerance and therapeutic goals. A new higher 7.2 mg weekly dose has been approved in some regions to enhance weight‑loss efficacy in clinical settings.
Patent & Intellectual Property
Semaglutide is protected by a broad patent portfolio covering compositions, formulations, and therapeutic uses. Key U.S. patents include:
- US11318191 – GLP‑1 compositions and uses, expires Feb 17, 2041
- US11478533 – Related formulation claim, expires May 13, 2040
- US12214017/US8129343B2 – Additional composition/use patents, expiring 2038‑2041
These extended protections help delay generic competition in major markets such as the U.S. until the late 2030s–early 2040s.
Frequently Asked Questions
Q
What is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the natural hormone GLP-1 to regulate appetite and blood sugar levels, aiding in weight management and improving metabolic health.
Q
How does Semaglutide work in the body?
It regulates blood glucose by stimulating insulin secretion and inhibiting glucagon release, which makes it highly effective for type 2 diabetes management and obesity-related studies.
Q
How is Semaglutide administered?
It is typically administered via a once-weekly subcutaneous injection.
Q
What is the common dosage for weight management?
Common dosing protocols range from 0.25 mg up to 2.4 mg weekly, with gradual titration. In some regions, a higher 7.2 mg weekly dose has been approved to enhance weight-loss efficacy.
Q
When do the key patents for Semaglutide expire?
Key U.S. patents protecting Semaglutide's compositions and therapeutic uses are set to expire between 2038 and 2041, which delays generic competition in major markets until that time.
